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Abstract: We tested the effect of chronic low-dose abscisic acid (ABA), a phytohormone-regulating
human glucose tolerance, on the metabolic parameters that are dysregulated in prediabetes and
metabolic syndrome (MS).Ten healthy subjects received 1 µg ABA/Kg body weight (BW)/day as
an ABA-rich food supplement: (i) the glycemia profile after a carbohydrate-rich meal, with or
without supplement, was compared; (ii) fasting blood glucose (FBG), glycated hemoglobin (HbA1c),
total cholesterol (TC), and body mass index (BMI) after 75 days of daily supplementation of a habitual
Mediterranean diet were compared with starting values.CD1 mice were fed a high-glucose diet with
or without synthetic ABA (1 µg/Kg BW) for 4 months and the same parameters investigated in the
human study were compared. The food supplement significantly reduced the area under the curve
of glycemia after a carbohydrate-rich meal and FBG, HbA1c, TC, and BMI after chronic treatment.
ABA-treated mice showed a significant reduction of HbA1c, TC, and body weight gain compared
with untreated controls. The combined results from the human and murine studies allow us to
conclude that the observed improvement of the metabolic parameters can be attributed to ABA and
to advocate the use of ABA-containing food supplements in prediabetes and/or MS.
Keywords: prediabetes; metabolic syndrome; food supplement; glucose tolerance; cardiovascular risk
1. Introduction
Type 2 diabetes mellitus (T2D) has reached epidemic proportions worldwide. It has been estimated
that, globally, over 8% of adults, corresponding to more than 380 million people, have T2D and this
number is set to rise beyond 600 million in less than 25 years [1]. Furthermore, the prevalence of insulin
resistance, the cause of prediabetes and an independent risk factor for cardiovascular disease and
metabolic syndrome (MS), is even more widespread [2–4]. To date, the number of prediabetic subjects
is estimated at 30 million in Europe and at 86 million in the United States (i.e., approximately 35% of
the U.S. population). While T2D is irreversible, prediabetes, the most important risk factor to develop
T2D, can be reverted to a healthy metabolic condition through lifestyle interventions, which require
a lifelong commitment, and suffer low compliance.
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While the appropriateness and cost-effectiveness of pharmacological interventions in prediabetic
subjects are being debated, nutraceuticals and food supplements are attracting attention as a viable
strategy to address the need for safe, lifelong interventions to reduce the risk of developing diabetes
and dyslipidemia. Botanicals have been extensively used in traditional medicine throughout the
world because of their effectiveness, limited side effects, and relatively low cost [5]. In particular,
some phytochemicals reported to possess hypoglycemic activity have been identified in vegetal extracts
such as Bitter melon, Fenugreek, Gymnema, and Morus Alba [6]. The mechanism of action of these
botanicals relies on stimulation of insulin secretion and/or reduction of intestinal glucose absorption [6].
The plant stress hormone abscisic acid (ABA) has recently been recognized as an animal hormone
involved in glycemia homeostasis [7,8]. Plasma ABA (ABAp) increases in healthy subjects after an oral
glucose load and impairment of this normal ABA response to hyperglycemia occurs in T2D and in
gestational diabetes (GDM) [9]. GDM is the only diabetic condition capable of spontaneous remission
to apparent normalcy (after childbirth). Interestingly, the plasma ABA response to a glucose load also
is restored after delivery; thus, resolution of the diabetic state after childbirth is accompanied by the
restoration of a normal ABA response to oral glucose [9]. Fasting ABAp was investigated before and
after biliopancreatic diversion (BPD) in obese, normal glucose tolerant (NGT) subjects, and in obese
T2D patients, in which resolution of diabetes was observed after BPD. Compared to pre-BPD values,
basal ABAp significantly increased 1 month after BPD in T2D as well as in NGT subjects, in parallel
with a reduction of fasting plasma glucose.
Altogether, these observations lend support to the hypothesis that endogenous (nanomolar) ABA
plays a critical role in normal glucose tolerance, and that low-dose exogenous ABA may provide
a means to improve glucose tolerance in prediabetes.
Impairment of the normal ABA response to hyperglycemia occurs in T2D [9], supporting the
hypothesis that ABA supplementation might improve glucose tolerance in prediabetes.
Indeed, a single ABA oral dose of 1 µg per Kg body weight (BW), in the form of an ABA-rich
vegetal extract or of synthetic ABA, reduces glycemia after glucose load in healthy humans or in rodents,
respectively [7]. The glycemia-lowering effect of low-dose ABA does not depend on stimulation of
insulin secretion, as insulinemia is reduced in ABA-treated compared with ABA-untreated controls.
The fact that low-dose ABA is not an insulin secretagogue sets ABA apart from most other current
therapeutics with glycemia-lowering action, which conversely stimulate insulin release and may
accelerate the beta cell demise that eventually occurs in T2D due to lifelong overstimulation.
The aim of this study was twofold: (i) to test the effect of an ABA-rich vegetal extract formulated for
human use on glycemia of healthy subjects taking a single carbohydrate-rich meal or fed a Mediterranean
diet for 75 days; (ii) to explore the effect of synthetic ABA on glycemia, lipidemia, and body weight in
mice fed a high-glucose diet for 4 months.
2. Materials and Methods
2.1. ABA-Containing Food Supplement
The ABA-containing food supplement was developed and notified to the Italian Ministry of
Health by Nutravis S.r.l. (Genova, Italy). It contained GSECM-50®, a vegetal source of ABA,
providing approximately 55 µg ABA/tablet.
2.2. Human Volunteers
Ten healthy volunteers (6 females and 4 males, aged between 31 and 58 years, mean age 43.6 years)
were enrolled. They were selected among 20 prospective candidates meeting the inclusion criteria (see
Table 1) because they showed values of fasting blood glucose (FBG) and/or of total cholesterol close to
or slightly above the normal upper limit at the beginning of the study. All subjects gave their informed
consent for inclusion before they participated in the study. The clinical trial was conducted in accordance
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with the Declaration of Helsinki, and the protocol was approved by the Ethical Regional Committee (ERC,
Genova, Italy; prot.031REG2016, 25 July 2016).
Table 1. Inclusion and exclusion criteria of the clinical study. (A) General inclusion and exclusion
criteria. (B) Composition of the Mediterranean diet exemplified during candidate selection. (C) A brief
demographic profile of the 10 selected participants is given below.
(A)
Inclusion Criteria Exclusion Criteria
1. Metabolic and physical parameters:
FBG ≤ 110 mg/dL; HbA1c ≤ 6.0%;
TC ≤ 260 mg/dL; BMI ≤ 26 Kg/m2;
age of ≥30 and ≤60 years.
All parameters stable during the past 12 months.
1. Metabolic parameters: metabolic parameters as in
the inclusion criteria met by medication; variation
of one or more parameter by ≥10% (5% for
HbA1c) of the value in the past 12 months.
2. Lifestyle: habitual Mediterranean diet *;
sedentary to recreationally moderately active
(≤2 days/week); ≤1 drink/day for women
and ≤2 drinks/day for men **; non- or
light-smoker (≤6 CPD).
2. Lifestyle: past or current self-imposed or
prescribed special dietary regimes; history of
eating disorders; daily or weekly physical routines
of vigorous intensity.
3. Medical examination: in general, good health
at the initial medical screening; BP ≤130/80
without anti-hypertensive medication;
participation approved by the Medical
Director of the study.
3. Medical history: past or current metabolic or
endocrine disorders, cardiovascular, neurological
or hematological diseases, chronic medication,
history of special dietary regimes; family history
of T2D and/or hyperlipidemia; planned or
current pregnancy; planned surgical procedures
during or immediately after the end of the study.
* As defined in refs [10–12]; ** Drink equivalents as defined in the 2015–2020 U.S. Dietary Guidelines for Americans;
FBG = fasting blood glucose, HbA1c = glycated hemoglobin, TC = total cholesterol, BMI = body mass index,
CPD = cigarettes per day, BP = blood pressure, T2D = type 2 diabetes mellitus.
(B)
Servings/Week
Vegetables 14
Fruits 21
Legumes 4
Fish 2
Nuts 3
Starches 14
White meat ≤300g
Red meat ≤100g
Olive oil as the only seasoning and cooking ingredient
(C)
Age
Mean: 43.6; median: 44.5
Mean age females: 46
Mean age males: 40
0–29 0
30–39 2 (20%)
40-49 6 (60%)
50–59 2 (20%)
≥60 0
Gender 4 males (40%) and 6 females (60%)
Ethnicity All participants were Caucasian
Educational
levels
University degree 9/10 (90%)
Diploma 1/10 (10%)
Marital status
Married 4/10 (40%)
Single 6/10 (60%)
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In the first experimental protocol, each subject introduced a standardized carbohydrate-rich
breakfast, one with and another without one tablet of the food supplement taken immediately before
the meal. The two experiments were scheduled 1week apart and were performed in the morning after
overnight fasting. Glycemia and plasma ABA (ABAp) were measured on blood samples taken before
(time zero) and 15, 30, 60, and 120 min after breakfast. Glycemia was measured with a glucometer
(Bayer, Milan, Italy) and ABAp was measured by ELISA [7]. All measures were performed in duplicate.
In the second experimental protocol, the volunteers were instructed not to change their dietary
habits during the study and to take one tablet of the ABA-containing food supplement daily before
breakfast. At the beginning of the study (day 1) and after 75 days of treatment, a blood sample
was taken from each subject after overnight fasting and waist circumference (WC) and body mass
index(BMI) were measured. Values of FBG, glycated hemoglobin (HbA1c), and total and HDL
cholesterol were determined by the clinical chemistry laboratory of the IRCCS San Martino in Genova.
2.3. Animals
Male CD1 mice (6-week old) purchased from Charles River (Milano, Italy) were housed at the
animal facility of the IRCCS San Martino. All protocols of animal use were approved (authorization 349,
Italian Ministry of Health, 30 August 2013). As the human prediabetic condition is believed to span
a time frame of approximately 15 years, between 30 and 45 years of age, the age of the mice and the
duration of treatment (4 months) were chosen in order to match the time frame at which prediabetes
develops in diabetes-prone humans.
2.4. Animal Study
Seven-week-old mice (nine/group) fed a standard chow were administered glucose in
the drinking water without (controls) or with synthetic (±)-2-cis, 4-trans abscisic acid (ABA)
(Sigma Aldrich, Milano, Italy). To achieve the required daily dose of glucose (1 g/Kg BW) and of ABA
(1 µg/Kg BW), the daily volume of water drank by the animals was preliminarily established. Based on
this volume (5 mL/day) and taking into account an average weight of the mice of 25 g, the water
administered to the animals contained 0.005 g/mL of glucose and 0.005 µg/mL of ABA. The animals
were weighed weekly and the concentrations of glucose and of ABA in the water were adjusted to
the mean BW in each cage. After 4 months of treatment, blood was drawn after overnight fasting to
measure HbA1c (Crystal Chem Inc., Elk Grove Village, IL, USA), total cholesterol, and triglycerides
(Abcam, Cambridge, UK) and body weight was measured.
2.5. Oral Glucose Tolerance Test (OGTT) in Mice
One week before the end of the 4-month high-glucose diet, mice were fasted for 17 h before
the OGTT. Then, 1 g/Kg BW of glucose was administered by gavage in a 150-µL water solution.
Blood was drawn from the tail vein before gavage (time zero) and 15, 30, 60, and 120 min after gavage.
Glycemia was immediately measured with a glucometer (Bayer, Milan, Italy), and each measure was
performed in duplicate.
2.6. Statistical Analysis
A power analysis was performed to calculate the number of participants in the human study and
the number of mice in the murine study, starting from results obtained in a previous investigation with
an ABA-rich vegetal extract on healthy humans and with synthetic ABA on rodents [7].
The normal distribution of the values obtained from the human and the murine experiments
was assessed with the Vassarstats website for statistical computation [13]. Continuous variables
are presented as mean ±SD. Comparisons were drawn by paired, one-tailed Student’s t-test, when
the same direction of change was observed in all values; if not, a two-tailed t-test was applied.
Statistical significance was always set at p < 0.05.
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3. Results
3.1. Intake of the ABA-Rich Food Supplement Reduces the Area under the Curve (AUC) of Glycemia
and Increases ABAp after a Standardized Carbohydrate-Rich Breakfast
Ten subjects (6 females and 4 males) ate a standardized carbohydrate-rich breakfast either without
(B w/o fs) or with (B+fs) one tablet of the food supplement. The dose of ABA taken by the subjects was
between 0.7 and 1.1 µg ABA/Kg BW considering their body weight (ranging between 51 and 80 Kg).
The composition of the standard meal is shown in Table 2. Carbohydrate intake was adjusted to the
mean body weight difference between male (72 Kg) and female (56 Kg) participants; thus, intake of
sugars was approx. 0.7 g/Kg body weight in both males and females.
Table 2. Composition of the standardized carbohydrate-rich breakfast.
Males Females
g or mL Carbohydrates(g/100g)
of which
Sugars (g/100g) g or mL
Carbohydrates
(g/100g)
of which
Sugars (g/100g)
Biscuits 117 79.2 22.5 78 52.8 15.0
Jam 50 29.0 25.0 50 29.0 25.0
Cornflakes 25 21.7 9.2 25 21.7 9.2
Milk 150 7.8 7.8 150 7.8 7.8
Total 137.7 64.5 111.4 57.0
Abscisic acid (ABA) content 3.1 µg 2.9 µg
The endogenous ABA content of the meal (approximately 3 µg) was determined by HPLC-MS
as described in [7]. Thus, the amount of ABA introduced with the B+fs was approximately 20-fold
compared with the B w/o fs. Glycemia and ABAp were measured on blood samples taken immediately
before (time 0) and 15, 30, 60, and 120 min after breakfast. A significant reduction of the mean glycemia
profile and of the mean AUC of glycemia was observed in the B+fs experiment compared with the
B w/o fs (Figure 1a,b). The mean AUC of ABAp was significantly higher in the subjects after the B+fs
as compared with the B w/o fs (Figure 1c), confirming previous results indicating that oral ABA is
absorbed [7]. This result indicates that intake of the ABA-rich food supplement increases plasma ABA
levels and reduces glycemia in 10 subjects after a standardized carbohydrate-rich breakfast.
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Figure 1. Ten healthy subjects introduced a standardized carbohydrate-rich breakfast, one with (B+fs)
and another without (B w/o fs) one tablet of the food supplement, taken immediately before the meal.
Mean ± SD values of (a) glycemia profiles; (b) area under the curve (AUC) of glycemia; (c) AUC of
plasma ABA (ABAp) are shown. p values by paired, one-tailed t-test.
3.2. The Daily Intake of the ABA-Containing Food Supplement for 75 Days Improves Metabolic Parameters in
Healthy Subjects without Dietary Restrictions
The results obtained in the breakfast experiments prompted us to test the effect of chronic intake
of the ABA-containing food supplement. One week after the end of the breakfast experiment, the same
subjects were instructed to take a daily tablet of the food supplement before breakfast and not to
change their feeding habits, which consisted of a typical Mediterranean diet, this being one of the
inclusion criteria (Table 1B). FBG, total and HDL cholesterol, WC, and BMI were measured at days 1
and 75 of the trial. No adverse effects of the treatment were reported.
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Table 3 summarizes the results obtained for each study participant.
Table 3. Individual metabolic and body mass parameters of 10subjects treated for 75 days with the ABA-rich food supplement.
Age FBG (mg/dL) HbA1c (%) TC (mg/dL) HDL (mg/dL) non-HDL-C (mg/dL) CVR BMI (Kg/m2) WC (cm)
#1 F 58 106 vs. 73 5.9 vs. 5.1 257 vs. 214 80 vs. 77 177 vs. 137 3.2 vs. 2.8 23.0 vs. 22.5 83 vs. 78
#2 M 49 92 vs. 84 4.9 vs. 4.7 222 vs. 149 49 vs. 56 173 vs. 93 4.5 vs. 2.7 25.5 vs. 24.3 105 vs. 95
#3 F 45 92 vs. 75 5.4 vs. 5.2 210 vs. 167 56 vs. 50 154 vs. 117 3.8 vs. 3.3 21.1 vs. 20.7 84 vs. 80
#4 M 40 98 vs. 57 5.3 vs. 5.0 207 vs. 157 48 vs. 45 159 vs. 112 4.3 vs. 3.5 21.3 vs. 20.8 90 vs. 86
#5 F 44 89 vs. 79 5.6 vs. 5.3 185 vs. 148 69 vs. 54 116 vs. 94 2.7 vs. 2.7 25.8 vs. 24.6 93 vs. 81
#6 M 30 86 vs. 66 5.1 vs. 4.9 171 vs. 189 48 vs. 60 123 vs. 129 3.6 vs. 3.1 22.8 vs. 22.5 89 vs. 87
#7 M 41 75 vs. 76 5.6 vs. 5.3 204 vs. 180 46 vs. 53 158 vs. 127 4.4 vs. 3.4 22.8 vs. 22.4 87 vs. 84
#8 F 47 93 vs. 72 5.0 vs. 5.1 211 vs. 191 54 vs. 62 157 vs. 129 3.9 vs. 3.1 24.2 vs. 23.2 81 vs. 77
#9 F 31 97 vs. 76 5.2 vs. 5.0 211 vs. 170 103 vs. 98 108 vs. 72 2.0 vs. 1.7 21.0 vs. 20.8 72 vs. 70
#10 F 51 96 vs. 71 5.0 vs. 4.8 190 vs. 182 78 vs. 72 112 vs. 110 2.4 vs. 2.5 21.0 vs. 20.6 83 vs. 79
Values recorded at days 1 and 75 of the study are shown for each parameter. FBG, fasting blood glucose; HbA1c, glycated hemoglobin; TC, total cholesterol; non-HDL-C, non-HDL
cholesterol, calculated as the difference between TC and HDL; CVR, cardiovascular risk, calculated as the ratio between TC and HDL; WC, waist circumference. “Borderline” values are
shaded in grey (see Results).
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FBG, HbA1c, total cholesterol (TC), and BMI were all reduced at day 75 compared with day 1
in all subjects, except in subject #6, who showed a slight increase of TC, and in subjects #7 and #8,
who showed very similar values for FBG and HbA1c at the start and end of the study. A significant
decrease of the mean values of FBG (−20.6%), HbA1c (−5.7%), TC (−15.4%), BMI (−3.1%), WC (−5.7%),
and cardiovascular risk (−17.2%) was observed after 75 days of treatment (Table 4).
Table 4. Pre- vs. post-treatment comparison of the metabolic parameters explored in 10subjects treated
for 75 days with the ABA-rich food supplement.
Parameter Day 1 Day 75 % Reduction p Value
FBG (mg/dL) 92 ± 8.2 73 ± 7.4 20.6 <0.001
HbA1c (%) 5.3 ± 0.3 5.0 ± 0.2 5.7 0.0066
Total cholesterol (mg/dL) 207 ± 23 175 ± 20 15.4 0.0014
BMI (Kg/m2) 22.9 ± 1.8 22.2 ± 1.5 3.1 <0.001
Waist circumference (cm) 87 ± 8.7 82 ± 7.0 5.7 <0.001
Cardiovascular risk 3.49 ± 0.9 2.89 ± 0.5 17.2 0.0048
Mean values± SD of each parameter were calculated on all study participants (see Table 3). Day 1= start of the
study; day 75= end of the study. The cardiovascular risk was calculated for each subject as the ratio between total
cholesterol and HDL. p value (day 1 vs. day 75) by paired, one-tailed t -test.
The percentage of decrease was even higher when calculated only in those subjects with the
highest starting value for a specific parameter (Table 5B, borderline subjects). These starting values
were close to, or indeed coincided with, borderline values identified by the American Diabetes
Association (ADA) guidelines for prediabetes (ADA Standard of Medical Care in Diabetes—2017) and
metabolic syndrome (ATPIII Guidelines 2013): FBG ≥ 100 mg/dL; HbA1c ≥ 5.7%; TC > 200 mg/dL;
non-HDL-C ≥ 160 mg/dL; WC ≥ 88 cm (females) and ≥ 102 cm (males); BMI ≥ 25 Kg/m2.
Table 5. Metabolic parameters of subjects with normal or borderline values at day 1, treated for 75 days
with the ABA-rich food supplement.
(A)
Parameter Normal Subjects (#) Day 1 Day 75 % Reduction p Value
FBG (mg/dL) 2; 3; 5; 6; 7; 8 88 ± 6.8 75 ± 6.1 13.8 ± 9.5 0.008
HbA1c (%) 2; 3; 4; 6; 8; 9; 10 5.1 ± 0.2 5.0 ± 0.2 3.0 ± 3.2 0.021
TC (mg/dL) 5; 6; 10 182 ± 9.8 173 ± 21.9 4.6 ± 15.3 n.s.
Non-HDL-C (mg/dL) 5; 6; 9; 10 115 ± 6 101 ± 24 12.3 ± 17.2 n.s.
BMI (Kg/m2) 1; 3;4; 6; 7; 9; 10 21.9 ± 1.0 21.5 ± 0.9 1.8 ± 0.4 <0.001
Waist circumference (cm) 1; 3; 6; 7; 8; 9; 10 83 ± 5.4 79 ± 5.4 4.1 ± 1.3 <0.001
Cardiovascular risk 1; 5; 9; 10 2.6 ± 0.5 2.4 ± 0.5 5.7 ± 10.1 n.s.
(B)
Parameter Borderline Subjects (#) Day 1 Day 75 % Reduction p Value
FBG (mg/dL) 1; 4; 9; 10 99 ± 5.7 69 ± 11.3 30.2 ± 8.7 0.003
HbA1c (%) 1; 5; 7 5.7 ± 0.2 5.2 ± 0.2 8.1 ± 4.7 0.050
TC (mg/dL) 1; 2; 3; 4; 7; 8; 9 217 ± 18.3 175 ± 21 19.3 ± 7.8 <0.001
Non-HDL-C (mg/dL) 1; 2; 3; 4; 7; 8 163 ± 10 119 ± 16 26.6 ± 10.4 0.001
BMI (Kg/m2) 2; 5; 8 25.2 ± 0.9 24.0 ± 0.7 4.5 ± 0.3 0.002
Waist circumference (cm) 2; 4; 5 96.0 ± 7.9 87.0 ± 7.1 9.0 ± 4.2 0.034
Cardiovascular risk 2; 3; 4;6; 7; 8 4.1 ± 0.4 3.2 ± 0.3 21.2 ± 11.0 0.005
Mean ± SD values of each parameter were calculated separately in “normal” (panel A) subjects (unshaded in
Table 3) and in borderline subjects (panel B), i.e., those with starting values of FBG ≥ 96 mg/dL, HbA1c ≥ 5.6%, TC
> 200 mg/dL, non-HDL-C ≥ 154 mg/dL; BMI > 24 Kg/m2, waist circumference ≥ 90 cm (grey-shaded in Table 3). p
by paired, one-tailed t-test; n.s., not significant. FBG, fasting blood glycemia; HbA1c, glycated hemoglobin; TC,
total cholesterol.
Thus, the mean percentages of reduction at day 75 compared with day 1 in the borderline vs. the
normal subjects were 30.2 vs. 13.8 for FBG, 8.1 vs. 3.0 for HbA1c, 19.3 vs. 4.6 for TC, 26.6 vs. 12.3 for
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non-HDL-C, 4.5 vs. 1.8 for BMI, 9.0 vs. 4.1 for WC, and 21.2 vs. 5.7 for cardiovascular risk (Table 5).
Indeed, borderline subjects improved significantly more than normal subjects at the end of the study
for all parameters investigated (Figure 2a).
When the Framingham score (ATPIII Guidelines 2013) was calculated for each subject at days
1 and 75, a reduction was observed in all but one subject (#10), with a highly significant difference
between the mean values at the start vs. the end of the study (Figure 2b). Accordingly, the 10-year
risk percentage value was also reduced in all subjects (except for #6 and #10), with a highly significant
difference between the mean values at day 1 vs. day 75 (Figure 2c).
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particularly when they are borderline.
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3.3. Daily Intake of Synthetic ABA at 1 µg/Kg BW Improves Metabolic Parameters in Mice Fed a High-Glucose Diet
Results obtained in the human study could have been biased by the absence of a “control”
(untreated or placebo-treated group) and by the presence of other molecules besides ABA in the
ABA-rich food supplement. To address these potential confounding issues, we tested the same
metabolic parameters on mice fed for 4 months a high-glucose diet (1 g/Kg BW) with or without
(control) 1 µg/Kg BW of synthetic ABA. An OGTT was performed after overnight fasting 1 week
before the end of treatment. The AUC of glycemia was significantly lower in the ABA-treated
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animals compared with controls (Figure 3a). At the end of treatment, HbA1c (Figure 3b), cholesterol,
and triglycerides (Figure 3c) were all significantly lower in the ABA-treated animals compared with
controls. Moreover, the body weight gain was reduced by 25% in the ABA-treated mice compared
with controls (Figure 3d). Altogether, the results obtained indicate that chronic low-dose synthetic
ABA significantly improved glucose tolerance and lipidemia in treated mice fed a high-glucose dietary
regimen compared with untreated controls.
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Seven-w ek-old male CD1 mice (nine/ ) ere fed for 4 months a i h-glucose diet co taining
1 g/Kg BW glucose (admini ith the drinking water) without (controls) or with ABA at
approximately 1 µg/Kg BW. At the end of the stu y, fasting HbA1c, lipidemia, and body weight were
measured and an OGTT was performed. (a) AUC of glycemia after OGTT, (b) HbA1c, (c) lipidemia,
(d) body weight. Mean ± SD values are shown. p values by unpaired, two-tailed t-test.
4. Discussion
The results of the human study indicate that a single dose of the ABA-containing food supplement
ameliorated the glycemia profile of 10healthy subjects after a standardized carbohydrate-rich breakfast
and that the daily intake of the food supplement for 75 days reduced FBG, HbA1c, TC, and body
weight in the same subjects fed a Mediterranean diet. Approximately the same daily dose of ABA
taken by each subject in the form of an ABA-containing vegetal extract (1 µg/Kg) was administered
with drinking water as a sy thetic m lecule to m ce fed a high-glucose diet for 4 nths. The murine
study confirms the significa r duction of glycated he oglobin, blood lipids, and body wei ht in
the ABA-treated group as compared with untreated controls, replicating with the pure hormone the
results obtained in humans with an ABA-containing vegetal extract.
The present study originates from a previous finding that low-dose oral ABA improves glucose
tolerance and reduces insulinemia in humans and rats [7,14]. The mechanism underlying the
insulin-sparing effect of ABA was hypothesized to rely on stimulation by ABA of muscle glucose uptake,
causing a reduction of blood glucose levels and consequently of insulin secretion. Indeed, in vitro
studies have demonstrated a direct, insulin-independent effect of ABA on GLUT4 expression and
membrane translocation in murine myoblasts [8]. Insulin-independent stimulation of glucose transport
in the skeletal muscle may account for the glycemia-lowering effect of ABA observed both under acute
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(Figure 1a) and chronic (Table 4) treatment. The sparing effect of ABA on insulin release may also
be partly responsible for the reduction of BMI and waist circumference observed in the clinical study
(Table 3) and the reduced body weight gain observed in the ABA-treated mice fed a high-glucose diet
(Figure 3d). Another possible mechanism underlying the effect of ABA on body mass is the recently
reported stimulation by chronic, low-dose ABA of the expression of brown adipose tissue (BAT) marker
genes in the white adipose tissue (WAT). In vitro, treatment of human and murine adipocytes with
ABA induces lower triglyceride accumulation and glucose-derived fatty acid synthesis compared with
insulin, increases transcription of adiponectin, and upregulates the expression of several BAT marker
genes, including energy-dissipating uncoupling protein-1 (UCP1). In vivo, a single dose of ABA at
1 µg/Kg increases BAT glucose uptake twofold in rats and ABA treatment at the same dose for 1 month
significantly increases expression of BAT genes in the WAT of treated mice [15].
Interestingly, the subjects with borderline values of FBG, TC, and/or BMI at the start of the study
benefited more from the daily supplementation with ABA. As summarized in Table 5B, the reduction of
FBG, TC, and HbA1c was significantly higher in the subjects with the highest levels at day 1 compared
with those who had lower starting values. Indeed, borderline subjects improved significantly more
compared with normal subjects for each parameter investigated (Figure 2a). This result suggests that
prediabetic subjects should benefit from oral low-dose ABA supplementation, similar to the borderline
subjects of this study. In this regard, it is noteworthy that the cardiovascular risk index was reduced by
a significantly higher percentage in the subjects with borderline values of TC compared with those
with normal starting TC values (Table 5B, Figure 2a).
Calculation of the Framingham point score for each subject at days 1 and 75 showed a reduction
of the score in all subjects, except for #10, yielding a highly significant mean reduction (Figure 2b).
Accordingly, the mean 10-year risk percentage value was also significantly decreased (Figure 2c).
Of note is that the significant improvement of the metabolic parameters occurred without lifestyle
interventions, such as dietary restrictions or increased physical activity. One of the inclusion criteria
was the dietary habit of a Mediterranean diet, defined on the basis of published criteria [10–12] and
investigated during the interview of the candidates (Table 1). All 10volunteers were instructed not
to change their dietary regimen or otherwise significantly modify their lifestyle during the study.
Thus, each individual subject at the start of the study was his/her own control.
It is possible that in subjects fed a high-fat and/or high-carbohydrate diet, the effect of the
ABA-containing nutraceutical could be different compared with what was observed in subjects under
a Mediterranean diet. A high-fat/high-carbohydrate diet should induce faster and more pronounced
changes in glucose and lipid tolerance (in diabetes-prone individuals) compared with a Mediterranean
diet. Since the subjects with borderline values were those who benefited more from the nutraceutical
intervention, it is possible that the beneficial effect of ABA supplementation may be more pronounced
under a dietary regimen that accelerates the onset of prediabetes.
Results obtained on the murine model lend support to the conclusion that ABA is indeed the
effective molecule in the food supplement. Rodents fed a high-glucose diet with synthetic ABA for
4 months show an improved glucose tolerance (Figure 3a,b) and reduced lipidemia and body weight
gain (Figure 3c,d) compared with ABA-untreated controls. Thus, the outcome of the study of chronic
ABA treatment in mice confirms that low-dose ABA improves the same metabolic parameters in rodents
as in humans and is certainly unaffected by the presence of other vegetal-derived molecules as in the
ABA-containing food supplement or by possible modifications of feeding behavior during the study.
The dose of ABA administered in the clinical and murine studies (1 µg/Kg BW) is not attainable from
a vegetal-rich diet, although ABA is present in most leafy vegetables, seeds, legumes, and fruits [7,14].
Thus, intake of a food supplement containing the appropriate amount of ABA is required to achieve
this dose. Absorption of ingested ABA has been already documented [7] and has been confirmed here
(Figure 1c), probably occurring by simple diffusion of the protonated molecule at pH values below the
pKa of ABA (4.6), such as those present in the stomach. The long half-life of ABA in the bloodstream,
inferred from the elevated ABAp levels observed in humans several hours after intake of an ABA-rich
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extract [7], is likely due to binding of ABA to plasma proteins. Indeed, ABA binding to fatty-acid-free
human albumin has been observed in vitro [7] and is reminiscent of the behavior of steroid and thyroid
hormones, which share a relatively long half-life. In addition to preventing rapid urinary excretion,
plasma protein binding of lipophylic hormones provides a natural slow-release reservoir, useful in
lifelong treatments, where a single daily dose replenishes the bound reservoir.
5. Conclusions
The combined results from the human and murine studies presented here provide a strong
rationale for the supplementation of human diet with microgram amounts of nutraceutical ABA
as a means to correct the initial derangement of the metabolic parameters (blood glucose, lipids,
and body weight) which are both symptomatic and pathogenetic of prediabetes and metabolic
syndrome. Nutraceutical ABA holds promise as a simple, low-cost, and easy-to-comply-with treatment
to address the urgent need for an affordable and effective means to prevent or delay the onset of
T2D and cardiovascular disease. In view of the social relevance of this goal, randomized clinical
studies on a higher number of prediabetic subjects are now justified to assess the beneficial potential of
nutraceutical ABA, also in combination with dietary regimens different from the Mediterranean diet.
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